查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1797334

全球注射剂市场

Infused Drugs
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 285 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年全球注射剂市场规模将达 118 亿美元

全球注射剂市场规模预计在2024年达到82亿美元，预计在分析期间（2024-2030年）将以6.2%的复合年增长率成长，到2030年将达到118亿美元。小分子药物是本报告分析的细分市场之一，预计其复合年增长率将达到7.5%，到分析期结束时达到76亿美元。生技药品细分市场在分析期间的复合年增长率预计为4.1%。

美国市场规模估计为 22 亿美元，中国市场预期复合年增长率为 10.0%

美国注射剂市场规模预计2024年达到22亿美元。作为世界第二大经济体，中国市场规模预计将在2030年达到25亿美元，2024年至2030年的复合年增长率为10.0%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间的复合年增长率分别为2.9%和6.1%。在欧洲，德国的复合年增长率预计将达到4.1%。

全球注射剂市场－主要趋势与驱动因素摘要

为什么注射剂在每个治疗领域都越来越受欢迎？

注射剂透过静脉或皮下注射直接进入血液或组织，对于需要快速、精准或长期给药的疾病至关重要。这些药物广泛用于肿瘤、自体免疫疾病、罕见疾病以及口服或局部治疗不足的慢性感染疾病。输注可以控制生物有效性，避免与胃肠道吸收不良和患者违规相关的问题。

生物製药和标靶治疗的进步正在扩大注射剂在类风湿性关节炎、多发性硬化症和癌症等疾病治疗中的作用。注射单株抗体、免疫疗法和酵素替代疗法提供了高度特异性、缓解疾病的治疗方案。随着个人化医疗的日益普及，注射剂可根据基因和生物标记物谱进行定制，从而提高复杂疾病领域的治疗精准度和疗效。

分娩系统和护理环境如何发展？

注射剂的管理正在从医院转向门诊、居家医疗和专科输液中心。可携式输液帮浦和简化的输液套件为需要长期照护的患者提供了更大的灵活性和舒适度。家庭输液服务正在透过远端监控和护理人员辅助给药进行扩展，尤其是对于需要反覆输液的慢性疾病。

药物输送系统也不断发展，包括智慧型帮浦、封闭式系统传输装置以及可延长输液间隔的製剂。这些创新降低了感染风险，增强了病人安全性，并提高了依从性。生技药品相似药输注正在高所得市场和新兴市场中推广，以降低治疗成本并提高药物可及性。製剂技术也不断优化，以缩短输液时间并减少输液相关反应。

哪些领域的市场需求不断增加？主要的最终用户是谁？

肿瘤科仍然是注射剂最大的应用领域，由于癌症发病率上升和标靶治疗应用的不断扩大，肿瘤科占据了全球输液药物需求的很大一部分。克隆氏症、牛皮癣和系统性红斑狼疮等自体免疫疾病也是输液药物使用的主要驱动因素。医院药局、门诊输液诊所和专科医疗中心是主要的给药地点。

已开发经济体和新兴经济体的需求都在成长。北美凭藉其专业的治疗中心和完善的报销框架，在输液产品的应用方面处于领先地位。欧洲紧随其后，大力推广生物相似药和家庭输液模式。亚太地区正经历成长，这得益于医疗保健可近性的提高、癌症筛检计画以及政府在慢性病照护方面的倡议。移植医学、感染疾病控制和罕见代谢疾病也推动了输液产品的需求。

是什么推动了注射剂市场的成长？

注射剂市场的成长受到多种因素的推动，包括慢性病和罕见疾病的日益普及、生物疗法的进步以及门诊和家庭输液服务的日益普及。包括携带式和可程式设计输液设备在内的输送系统的技术改进，正在为更安全、更便捷的治疗环境提供支援。输液免疫疗法和长效生物生物製药在自体免疫疾病和肿瘤学领域的应用不断扩大，也推动了市场需求。

扩大门诊、专科诊所和家庭输液计画的终端使用范围，正在提高治疗的可近性，同时减轻住院治疗的成本负担。生物相似药的开发以及支持家庭输液的付费方计划正在创造具有成本效益的治疗途径。精准医疗和伴随诊断的作用日益增强，推动了对具有针对性作用机制的高效注射剂的需求。这些趋势共同推动了涵盖多个疾病领域和护理模式的全球输液治疗市场的发展。

部分

药物类型（小分子、生物）、治疗领域（癌症、消化系统疾病、类风湿性关节炎、免疫力缺乏、循环系统疾病、神经系统疾病、糖尿病、其他治疗领域）

受访公司范例

  • AbbVie Inc.
  • Amgen Inc.
  • Amneal Pharmaceuticals Inc.
  • Apotex Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • Hikma Pharmaceuticals plc
  • Parenteral Drugs（India）Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Stada Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.
  • Weefsel Pharma（Weefsel Biopharma）
  • Wockhardt Ltd.
  • Zydus Cadila

人工智慧集成

我们正在利用有效的专家内容和人工智慧工具来改变市场和竞争情报。

Global 特定产业产业SLM 的典型规范，而是建立了一个从世界各地专家收集的内容库，包括影片录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP38949

Global Infused Drugs Market to Reach US$11.8 Billion by 2030

The global market for Infused Drugs estimated at US$8.2 Billion in the year 2024, is expected to reach US$11.8 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Small Molecules Drug, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$7.6 Billion by the end of the analysis period. Growth in the Biologics Drug segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 10.0% CAGR

The Infused Drugs market in the U.S. is estimated at US$2.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Infused Drugs Market - Key Trends & Drivers Summarized

Why Are Infused Drugs Gaining Preference Across Therapeutic Areas?

Infused drugs, administered directly into the bloodstream or tissue via intravenous or subcutaneous routes, are essential in managing conditions that require rapid, precise, or long-duration dosing. These drugs are widely used in oncology, autoimmune diseases, rare disorders, and chronic infections where oral or topical treatments are inadequate. Infusion allows for controlled bioavailability and bypasses issues related to poor gastrointestinal absorption or patient non-compliance.

Advances in biologics and targeted therapies have expanded the role of infused drugs in treating conditions such as rheumatoid arthritis, multiple sclerosis, and cancer. Infused monoclonal antibodies, immunotherapies, and enzyme replacement therapies are providing highly specific, disease-modifying treatment options. As personalized medicine becomes more prevalent, infused drugs are being tailored based on genetic and biomarker profiles, improving therapeutic precision and outcomes in complex disease areas.

How Are Delivery Systems and Care Settings Evolving?

The administration of infused drugs is shifting beyond hospitals to outpatient clinics, home care, and specialized infusion centers. Portable infusion pumps and simplified infusion kits are enabling greater flexibility and comfort for patients requiring long-term treatment. Home infusion services are expanding, particularly for chronic conditions that need recurrent dosing, supported by remote monitoring and nurse-assisted administration.

Drug delivery systems are also advancing with smart pumps, closed-system transfer devices, and formulations that allow extended infusion intervals. These innovations reduce infection risks, increase patient safety, and improve adherence. Biosimilar versions of infused biologics are being introduced to reduce treatment costs and improve access in both high-income and emerging markets. Formulation technologies are also being optimized to shorten infusion times and reduce infusion-related reactions.

Where Is Market Demand Increasing, and Who Are the Main End-Users?

Oncology remains the largest segment for infused drugs, accounting for a substantial share of global demand due to the rise in cancer incidence and expanded use of targeted therapies. Autoimmune diseases such as Crohn’s disease, psoriasis, and systemic lupus are also major contributors to infusion drug usage. Hospital pharmacies, outpatient infusion clinics, and specialty care centers are the primary settings for administration.

Demand is increasing in both developed and developing countries. North America leads in utilization due to the presence of specialized treatment facilities and reimbursement frameworks. Europe follows with strong adoption of biosimilars and home-based infusion models. Asia Pacific is experiencing growth due to rising healthcare access, cancer screening programs, and government-backed chronic care initiatives. Infusion drug demand is also supported by transplant care, infectious disease management, and rare metabolic disorders.

What Is Driving Growth in the Infused Drugs Market?

Growth in the infused drugs market is driven by several factors including increasing incidence of chronic and rare diseases, advances in biologic therapies, and rising adoption of outpatient and home-based infusion services. Technological improvements in delivery systems, including portable and programmable infusion devices, are supporting safer and more convenient treatment settings. Demand is also supported by expanding indications for infused immunotherapies and long-acting biologics across autoimmune and oncology domains.

End-use expansion in ambulatory care, specialty clinics, and home infusion programs is increasing treatment accessibility while reducing the cost burden of inpatient administration. Development of biosimilars and payer initiatives to support home infusions are creating cost-effective treatment pathways. The growing role of precision medicine and companion diagnostics is strengthening demand for high-efficacy infused drugs with targeted mechanisms of action. These trends are collectively reinforcing the global market for infused therapies across multiple disease areas and care models.

SCOPE OF STUDY:

The report analyzes the Infused Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Small Molecules Drug, Biologics Drug); Therapeutic Area (Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Diabetes Therapeutic Area, Other Therapeutic Areas)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • Amneal Pharmaceuticals Inc.
  • Apotex Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • Hikma Pharmaceuticals plc
  • Parenteral Drugs (India) Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Stada Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.
  • Weefsel Pharma (Weefsel Biopharma)
  • Wockhardt Ltd.
  • Zydus Cadila

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Infused Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic and Autoimmune Diseases Drives Demand for Long-Term Administration of Infused Therapies
    • Expansion of Biologic Drug Development Pipelines Strengthens Growth in IV-Delivered Monoclonal Antibodies and Targeted Treatments
    • OEM Innovation in Formulation Stability and Infusion Device Compatibility Enhances Safety and Efficacy of Infused Medications
    • Growing Shift Toward Outpatient and Home Infusion Models Throws Spotlight on Portable and Self-Administered Infusion Systems
    • Surge in Cancer Treatment Protocols Involving Chemotherapy and Immunotherapy Supports Use of Infused Drug Regimens
    • OEM Focus on Closed-System Drug Transfer Devices and Catheter Safety Enhances Risk Management During Infusion Procedures
    • Increasing Role of Specialty Pharmacies and Infusion Clinics Promotes Access to High-Cost Infused Therapies
    • Expansion of Value-Based Care Models Drives Emphasis on Cost-Effectiveness and Outcome Monitoring for Infused Drugs
    • OEM Integration of Infusion Monitoring Software With EHR Systems Improves Documentation and Clinical Oversight
    • Rising Demand for Personalized Dosing and Weight-Based Infusion Protocols Supports Precision Medicine Approaches
    • Growth in Pediatric and Rare Disease Therapies Fuels Innovation in Low-Volume, High-Potency Infused Drug Formats
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Infused Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Infused Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Infused Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Infused Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Small Molecules Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Small Molecules Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Small Molecules Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biologics Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biologics Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Biologics Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Oncology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Gastrointestinal Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Gastrointestinal Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Gastrointestinal Diseases Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Rheumatoid Arthritis Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Rheumatoid Arthritis Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Immune Deficiencies Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Immune Deficiencies Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Immune Deficiencies Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cardiology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cardiology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Cardiology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Neurology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Neurology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Neurology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Diabetes Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Diabetes Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Diabetes Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • JAPAN
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • CHINA
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: China 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: China 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • EUROPE
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Infused Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Infused Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Infused Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • FRANCE
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: France 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 71: France Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: France 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • GERMANY
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 89: UK Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Spain 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Russia 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Rest of Europe 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Infused Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Infused Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Infused Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Australia 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • INDIA
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 125: India Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: India 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 128: India Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: India 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: South Korea 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Infused Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Infused Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Infused Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Argentina 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Brazil 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Mexico 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Rest of Latin America 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Infused Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Infused Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Infused Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Iran 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Israel 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Saudi Arabia 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: UAE 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Rest of Middle East 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • AFRICA
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Africa 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030

IV. COMPETITION